Drug profile · INN
atovaquone
ATOVACUE
atovaquone (ATOVACUE) is a cytochrome b inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — atovaquone
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 1
- Data quality
- 0.89
Quick answer
atovaquone (ATOVACUE) is a cytochrome b inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cytochrome b inhibitor
Primary target: Cytochrome b
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Congress & event coverage
- PresentationASCO 2026
- PresentationASCO
- PresentationBio-IT World Conference
Pipeline programs
Related patents
Frequently asked questions
What is atovaquone?
atovaquone (ATOVACUE) is a cytochrome b inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for atovaquone?
ATOVACUE is a marketed brand name for atovaquone. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of atovaquone?
atovaquone has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.